Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03793582 · ClinicalTrials.gov registry record

Impact of OSA on Outcomes in Acute Coronary Syndrome

A clinical trial of OSA and ACS (Acute Coronary Syndrome), sponsored by MetroHealth Medical Center.

Completed
Registry status
128
Enrollment target
1
Study location

NCT03793582 is a study of OSA and ACS (Acute Coronary Syndrome) that has completed, run by MetroHealth Medical Center. The registered enrollment target is 128 participants, below the 156-participant average among 14 other OSA trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03793582, a study of OSA and ACS (Acute Coronary Syndrome), has completed, sponsored by MetroHealth Medical Center.

COMPLETED
Registry status
128 participants
Enrollment target
1
Study location

Study Summary

Elucidating the effects of obstructive sleep apnea (OSA) on cardiovascular outcomes in acute coronary syndrome (ACS) is crucial in risk assessments and therapeutic recommendations for affected individuals. Although large epidemiological studies have reported an association between OSA and both coronary heart disease (CHD) and heart failure (HF), its effect on outcomes in ACS is still unclear. In contrast to previous theories attributing causation to OSA, recent studies have hypothesized a cardio protective role of OSA. Repetitive hypoxemic episodes noted in OSA may lead to myocardial ischemic preconditioning, possibly by increasing coronary collateral vessel recruitment, conferring protection from acute coronary events. We propose a prospective, observational, single center study in patients presenting with ACS, including ST segment elevation (STEMI), non-ST segment elevation (NSTEMI) and unstable angina who undergo coronary revascularization to determine the impact of OSA on clinical outcomes after ACS. Adult patients above age 18 years who present with myocardial infarction are eligible. Recruited patients will undergo an overnight sleep study using a level III portable diagnostic device before hospital discharge. The sleep tracings will be analyzed and audited by a certified sleep physician. The patients will be divided into 2 groups based on apnea-hypopnea index (AHI): OSA (AHI ≥ 15) and non-OSA (AHI \< 15) groups. The primary end points of this study were in-hospital, 30 day and 6 month major adverse cardiovascular events (MACE), defined as a composite endpoint of cardiovascular death, non-fatal MI, stroke and the need for unplanned repeat revascularization. Secondary endpoints include individual MACE outcomes of cardiovascular death, non-fatal MI, stroke, need for unplanned repeat revascularization, heart failure requiring hospitalization, and all-cause mortality.

Interventions

  • DIAGNOSTIC_TEST ApneaLink Type III portable sleep study

Study Locations (1)

Ohio

  • MetroHealth Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2017-08-29
Est. Completion 2019-12-31

Sponsor

MetroHealth Medical Center

76 total trials

What the Registry Record Tells You About NCT03793582

The ClinicalTrials.gov registry entry for NCT03793582 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 14 other OSA trials with a reported enrollment target (18% lower). The listed sponsor is MetroHealth Medical Center, which has 76 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with OSA appearing as the primary indexed condition, and to 1 intervention - of which ApneaLink Type III portable sleep study is the first listed.

NCT03793582 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03793582 about?

NCT03793582 is a clinical study titled "Impact of OSA on Outcomes in Acute Coronary Syndrome". Elucidating the effects of obstructive sleep apnea (OSA) on cardiovascular outcomes in acute coronary syndrome (ACS) is crucial in risk assessments and therapeutic recommendations for affected individuals. Although large epidemiological studies have reported an association between OSA and both coron...

What is the current status of trial NCT03793582?

This trial is currently completed. The enrollment target is 128 participants. The study started on 2017-08-29. Estimated completion is 2019-12-31.

What conditions does trial NCT03793582 study?

This clinical trial studies the following conditions: OSA, ACS (Acute Coronary Syndrome), Major Adverse Cardiac Events.

What interventions are being tested in trial NCT03793582?

The interventions under investigation include: ApneaLink Type III portable sleep study (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03793582?

This trial is sponsored by MetroHealth Medical Center, which has 76 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03793582 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for OSA

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.